Prevalence of comorbidities in elderly cancer patients

Wenkstetten-Holub, Alfa; Fangmeyer-Binder, Maria; Fasching, Peter

doi:10.1007/s12254-020-00657-2

Cited by 16 publications

(13 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The majority of patients in this study, approximately 65%, had mild or moderate comorbidity (CCI score 1–2), although the percentage of patients with high comorbidity (CCI score ≥ 3) increased progressively throughout the study period, an increase that was already observed in the previous decade [ 36 ]. It is known that the prevalence of comorbidities increases with age, making cancer patients more vulnerable [ 25 – 27 ]. The percentage of male patients aged 80 years or older increased by 8% throughout the study period, while in women, this percentage decreased by 13.4%.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Trends in hospitalization and in-hospital mortality rates among patients with lung cancer in Spain between 2010 and 2020

et al. 2022

View full text Add to dashboard Cite

Background Lung cancer is the third most frequent tumor and the main cause of death by tumor in Spain. Although the incidence and mortality are still significantly higher in men than in women, the disparity between the sexes is decreasing. The objective of this study was to analyze the evolution of lung cancer hospitalization and in-hospital mortality rates in Spain from 2010 to 2020. Methods The reports of the Minimum Basic Data Set (MBDS) at hospital discharge were used to retrospectively analyze the data of all patients with a primary diagnosis of lung cancer, according to the International Classification of Diseases (ICD-9-CM and ICD-10-CM). Results Between 2010 and 2020, there were 315,263 hospitalizations and 70,490 deaths from lung cancer in Spain, the majority (~ 80%) in men. Overall, the rates of hospitalization and in-hospital mortality from lung cancer showed a downward trend throughout the period, although the number of new diagnoses and the absolute number of deaths in women increased. Due to the aging of the population, the degree of comorbidity in patients with lung cancer, although it remains relatively low, is also on the rise. Conclusion Lung cancer represents a substantial clinical and economic burden for patients and for the National Health System, so it is necessary to promote primary prevention campaigns, as well as to develop more effective population screening measures to detect cancers early and increase the patient survival.

show abstract

Section: Discussionmentioning

confidence: 99%

“…According to data from the Spanish Lung Cancer Group's registry of thoracic tumors, the average age at diagnosis of patients with lung cancer in Spain is 64 years [23]. In the past 50 years, the average age of patients has been increasing progressively [24] along with associated comorbidities [25][26][27].…”

Section: Introductionmentioning

confidence: 99%

Trends in hospitalization and in-hospital mortality rates among patients with lung cancer in Spain between 2010 and 2020

et al. 2022

View full text Add to dashboard Cite

show abstract

“…al. [5], showed that Comorbid conditions in the elderly (>70 years) resulted in diminished ability to undergo intracavitary brachytherapy. Tumor recurrence and death from cervical cancer were more common in the elderly group.…”

Section: Discussionmentioning

confidence: 99%

Comparison of dose volume histograms and international commission of radiation units and measurement point doses to bladder and rectum in carcinoma cervix patients treated with intracavitary brachytherapy in department of radiotherapy

Priya

Benjamin

Sagar

2022

SR:MS

View full text Add to dashboard Cite

International commission of radiation units and measurement point doses to the bladder and rectum in carcinoma cervix patients treated with intracavitary brachytherapy in the department of radiotherapy. The aim: to evaluate two-dimensional point-based dose planning and three-dimensional computed tomography-based dose-volume parameters for high-dose-rate intracavitary brachytherapy of cervical cancer. Materials and methods: prospective study done between the years June 2018 to April 2020, a total of 50 prospectively registered women of non-metastatic carcinoma cervix treated with definitive concurrent chemo-radiotherapy followed by HDR intracavitary brachytherapy who met inclusion criteria were accrued in the study. All women in the study were treated with 50 Gy EBRT then assessment was done for response and adequacy for comfortable insertion of application. Brachytherapy procedure was performed under sedation in the lithotomy position. Results: Median age of the entire group was 54.5 years, majority of them were in their 5th (34 %) or 4th (28 %) decade. Pathologically, all were squamous cell carcinoma. Most common subtype was large cell non keratinizing type (64 %). Major bulk of the study is contributed by stage IIA, IIB, IIIB. All patients were treated with external beam radiotherapy of 50Gy in 25 fractions with 2Gy per fraction followed by high dose rate brachytherapy of 7 Gy per fraction for 3 fractions, one week apart to a total intracavitary brachytherapy dose of 21Gy. Conclusion: Results from the study suggests that rectum ICRU reference points can be surrogate markers for D2cc, but not for bladder and hence reporting should preferably be done in volumetric method rather than reference point doses

show abstract

“…However, grade 3–4 toxicity is also significantly increased and may not be suitable for frail patients. Surgery may not be an option for those patients because of pre-existing comorbidity and high mortality rate ( 4 , 5 ). In fact, older age by itself is the strongest predictor of non-treatment.…”

Section: Introductionmentioning

confidence: 99%

Is immunotherapy at reduced dose and radiotherapy for older patients with locally advanced non-small lung cancer feasible?—a narrative review by the international geriatric radiotherapy group

Vinh‐Hung¹,

Gorobets²,

Duerinkcx³

et al. 2022

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background and Objectives: The standard of care for locally advanced non-small cell lung cancer (NSCLC) is either surgery followed by adjuvant chemotherapy with or without radiotherapy or concurrent chemotherapy and radiotherapy. However, older patients (70 years old or above) with multiple co-morbidities may not be able to tolerate the combined treatment due to its toxicity. Since lung cancer prevalence increases significantly with age, a new algorithm needs to be investigated to allow curative treatment for those with locally advanced disease.Methods: A literature search of the literature was conducted through PubMed and Google Scholar using search terms such as locally advanced NSCLC, older cancer patients, immunotherapy with check point inhibitors (CPI), and image-guided radiotherapy (IGRT). Abstracts were screened, full articles fitting the article topic were reviewed, and duplicated and non-English articles were excluded.Key Content and Findings: Recently, CPI has been introduced and proven effective for selected patients with increased program death ligand 1 (PD-L1) expression (50% or above). A reduced dose for CPI (RDCPI) may be as effective as a full dose and may decrease treatment cost. New radiation technique such as IGRT may also minimize radiotherapy complication through normal lung and cardiac sparing.Conclusions: IGRT and RDCPI may be an innovative option for older patients with locally advanced NSCLC and high PD-L1 expression and needs to be investigated in future prospective studies.

show abstract

Prevalence of comorbidities in elderly cancer patients

Cited by 16 publications

References 28 publications

Trends in hospitalization and in-hospital mortality rates among patients with lung cancer in Spain between 2010 and 2020

Trends in hospitalization and in-hospital mortality rates among patients with lung cancer in Spain between 2010 and 2020

Comparison of dose volume histograms and international commission of radiation units and measurement point doses to bladder and rectum in carcinoma cervix patients treated with intracavitary brachytherapy in department of radiotherapy

Is immunotherapy at reduced dose and radiotherapy for older patients with locally advanced non-small lung cancer feasible?—a narrative review by the international geriatric radiotherapy group

Contact Info

Product

Resources

About